Program
zongertinib
Also written as “Zongertinib”, “zongertinib (C-14)” and “Zongertinib, Formulation A, reference product”.
Its studies are mostly in Lung Neoplasms · Carcinoma, Non-Small-Cell Lung · Breast Neoplasms · Neoplasm Metastasis · Liver Diseases, led by Boehringer Ingelheim.
Drug pageZongertinib: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheim | 157 open or running | phase 3since Nov 22, 2023 | May 4, 2021 | Dec 10, 2026phase 3 · NCT06151574 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Before these, 1 study since May 4, 2021.
- Jan 19, 2023Named zongertinibINNProposed as its International Nonproprietary Name in WHO's List 128
- Feb 28, 2023Phase 1 study in HealthyNCT05833139 · 16 enrolled · Germany
- May 25, 2023Phase 1 study in HealthyNCT05879991 · 15 enrolled · Netherlands
- Aug 30, 2023Phase 1 study in HealthyNCT06028464 · 16 enrolled · Germany
- Oct 4, 2023Phase 1 study in HealthyNCT06075277 · 16 enrolled · Germany
- Nov 22, 2023Phase 3 study in Lung NeoplasmsNCT06151574 · 428 enrolled · United States, Argentina, Australia and more
- Mar 15, 2024Phase 2 study in Breast NeoplasmsNCT06324357 · 910 planned · United States, Belgium, China and more
- Jul 3, 20242 phase 1 studies in HealthyNCT06494761, NCT06504862
- Aug 30, 2024Phase 2 study in Solid TumoursNCT06581432 · 588 planned · United States, Australia, Belgium and more
- Nov 15, 2024Phase 1 study in Liver DiseasesNCT06692322 · 29 enrolled · United States
- Sep 25, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07195695 · 400 planned · United States, Argentina, Australia and more
- Mar 12, 2026Phase 2 study in Lung NeoplasmsNCT07486817 · 60 planned · Australia, China, France and more
- Jun 11, 2026Phase 1 study in HealthyNCT07649941 · 16 enrolled · Germany
- Aug 24, 2026Phase 1 study in HealthyNCT07789028 · 56 planned · Germany
- Oct 28, 2026Primary completion moved from 2026-12-30 to 2028-02-29Date moved laterphase 1 · +14 months · NCT04886804
Ahead
- Dec 10, 2026Primary completion: phase 3 study in Lung NeoplasmsNCT06151574
- Dec 15, 2026Primary completion: phase 1 study in HealthyNCT07789028
- Aug 12, 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07486817
- Feb 29, 2028Primary completion: phase 1 study in Neoplasm MetastasisNCT04886804
TargetBeta
“An orally bioavailable inhibitor of the receptor tyrosine kinase human epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), ”NCIt, by rule
Other programs on ERBB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Trastuzumabrule | Hoffmann-La Roche | phase 4 | 85 |
| pertuzumabrule | Hoffmann-La Roche | phase 4 | 56 |
| trastuzumab deruxtecanrule | Daiichi Sankyo | phase 4 | 49 |
| tucatinibrule | Pfizer | phase 4 | 25 |
| disitamab vedotin | RemeGen | phase 3 | 36 |
| trastuzumab rezetecanrule | Jiangsu HengRui Medicine | phase 3 | 36 |
| Lutetium-177 | Novartis | phase 3 | 24 |
| trastuzumab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 21 |
| Gallium-68 | Philogen | phase 3 | 17 |
| Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 | Sino Biopharmaceutical | phase 3 | 13 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| anbenitamab | CSPC Pharmaceutical Group | phase 3 | 12 |
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07789028Healthy · Germany | 1 | Recruiting | Dec 15, 2026 | 56 |
| NCT07649941Healthy · Germany | 1 | Completed | Jul 31, 2026 | 16 |
| NCT07486817Lung Neoplasms · Australia, China, France and more | 2 | Recruiting | Aug 12, 2027 | 60 |
| NCT07195695Carcinoma, Non-Small-Cell Lung · United States, Argentina, Australia and more | 3 | Recruiting | Feb 26, 2032 | 400 |
| NCT06692322Liver Diseases · United States | 1 | Completed | Jun 20, 2025 | 29 |
| NCT06581432Solid Tumours · United States, Australia, Belgium and more | 2 | Recruiting | Nov 30, 2028 | 588 |
| NCT06504862Healthy · Germany | 1 | Completed | Oct 3, 2024 | 32 |
| NCT06494761Healthy · Germany | 1 | Completed | Oct 16, 2024 | 16 |
| NCT06324357Breast Neoplasms · United States, Belgium, China and more | 2 | Recruiting | Jan 8, 2029 | 910 |
| NCT06151574Lung Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Dec 10, 2026 | 428 |
| NCT06075277Healthy · Germany | 1 | Completed | Jan 2, 2024 | 16 |
| NCT06028464Healthy · Germany | 1 | Completed | Dec 8, 2023 | 16 |
| NCT05879991Healthy · Netherlands | 1 | Completed | Oct 19, 2023 | 15 |
| NCT05833139Healthy · Germany | 1 | Completed | Jun 12, 2023 | 16 |
| NCT04886804Neoplasm Metastasis · United States, Australia, Austria and more | 1 | Recruiting | Feb 29, 2028 | 554 |
How it is read
Names in the registry
- “Zongertinib”, 9 entries
- “zongertinib”, 5 entries
- “zongertinib (C-14)”, 2 entries
- “Zongertinib, Formulation A, reference product”, 1 entry
- “Zongertinib Formulation B, test product”, 1 entry
Conditions, from the studies’ own filings
- Lung Neoplasms, 2 studies
- Carcinoma, Non-Small-Cell Lung, 1 study
- Breast Neoplasms, 1 study
- Neoplasm Metastasis, 1 study
- Liver Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.